Aggressive behaviour in adults with intellectual disability: Defining the role of drug treatment

CNS Drugs

Volumn 23, Issue 11, 2009, Pages 903-913

  Oliver Africano, Patricia ^a   Murphy, Declan ^b   Tyrer, Peter ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; ZUCLOPENTHIXOL;

AGGRESSION; AUTISM; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DYSTONIA; ENVIRONMENTAL CHANGE; EVOLUTIONARY ADAPTATION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; MANIPULATIVE MEDICINE; NIDOTHERAPY; NOTE; PERSONALITY TEST; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; AGGRESSION; ANGER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; HUMANS; MENTAL RETARDATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70350345574     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11310930-000000000-00000     Document Type: Note

References (70)

1. Tyrer P, Tyrer S. Other treatments for persistent disturbances of behaviour. In: Tyrer P, Silk K, editors. Cambridge handbook of essential treatments in psychiatry. Cambridge: Cambridge University Press, 2008: 682-689
2. Strydom A, Livingston G, King M, et al. Prevalence of dementia in intellectual disability using different diagnostic criteria. Br J Psychiatry 2007; 191: 150-157
3. Emerson E, McGill P, Mansell J. Severe learning disabilities and challenging behaviours: designing high quality services. London: Chapman and Hall, 1994
4. Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a functional analysis of self injury. Anal Intervent Devel Disabil 1982; 2: 1-20
5. O'Neill RE, Horner RH, Albin RW, et al. Functional analysis of problem behavior: apractical assessment guide. 2nd ed. Pacific Grove (CA): Brooks/Cole, 1997
6. Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomised controlled trials. Cochrane Database Syst Rev 2007; (3): CD000377
7. Cooper SA, Smiley E, Morrison J, et al. Mental ill health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007; 190: 27-35
8. Jones S, Cooper SA, Smiley E, et al. Prevalence of, and factors associated with, problem behaviors in adults with intellectual disabilities. J Nerv Ment Dis 2008; 196: 678-686
9. Tenneij NH, Koot HM. Incidence, types and characteristics of aggressive behaviour in treatment facilities for adults with mild intellectual disability and severe challenging behaviour. J Intellect Disabil Res 2008; 52: 114-124
10. Smiley E, Cooper S-A, Finlayson J, et al. Incidence and predictors of mental ill-health in adults with intellectual disabilities. Br J Psychiatry 2007; 191: 313-319 (Pubitemid 47555979)
11. Emerson E, Hatton C. Mental health of children and adolescents with intellectual disabilities in Britain. Br J Psychiatry 2007; 191: 493-499
12. Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Dis 2001; 22: 77-93
13. Smith S, Branford D, Collacott DA, et al. Prevalence and cluster typology of maladaptive behaviors in a geographically defined population of adults with learning disabilities. Br J Psychiatry 1996; 169: 219-227
14. Alexander R, Cooray S. Diagnosis of personality disorders in learning disability. Br J Psychiatry 2003; 182 (44 Suppl.): s28-31
15. Kiernan C, Reeves D, Alborz A. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. J Intellect Disabil Res 1995; 39: 263-274
16. Branford D. A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. J Intellect Disabil Res 1994; 38
17. Linaker OM. Frequency and determinants for psychotropic drug use in an institution for the mentally retarded. Br J Psychiatry 1990; 156: 525-530
18. Thalayasingam S, Alexander RT, Singh I. The use of clozapine in adults with intellectual disability. J Intellect Disabil Res 2004; 48: 572-579
19. Haessler F, Glaser T, Beneke LJ, et al. Zuclopenthixol in aggressive challenging behaviour in learning disability: discontinuation study. Br J Psychiatry 2007; 190: 447-448
20. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 2003; 64: 1258-1265
21. Van den Borre R, Vermote R, Buttiens M, et al. Risperidone as add-on therapy in behavioral disturbances in mental-retardation: a double-blind placebo-controlled cross-over study. Acta Psychiat Scand 1993; 87: 167-171
22. Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children adolescents and adults with mental retardation. J Autism and Dev Disord 2006; 36: 401-411
23. Gagiano C, Read S, Thorpe L, et al. Short and long-term efficacy and safety of risperidone in adults with disruptive behaviour disorders. Psychopharmacol (Berl) 2005; 179: 629-636
24. Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371: 57-63
25. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 1001-1008
26. Janowsky DS, Shetty M, Barnhill LJ, et al. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Int J Neuropsychopharmacol 2005; 8: 37-48
27. Branford D, Bhaumik S, Nai K. Selective serotonin reuptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998; 42: 301-306
28. Tyrer SP, Walsh A, Edwards DE, et al. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progr Neuropsychopharmacol Biol Psychiatry 1984; 8: 751-755
29. Craft M, Ismail IA, Krisnamurti D, et al. Lithium in the treatment of aggression in mentally handicapped patients: a double-blind trial. Br J Psychiatry 1987; 150: 685-689
30. Taylor JL, Novaco RW, Gillmer B, et al. Cognitive-behavioural treatment of anger intensity among offenders with intellectual disabilities. J Appl Res Intellect Disabil 2002; 15: 151-165
31. Willner P, Jones J, Tams R, et al. A randomised controlled trial of the efficacy of a cognitive-behavioural anger management group for adults with learning disabilities. J Appl Res Intellect Disabil 2002; 15: 224-235
32. UK Clinical Research Network. UKCRN ID 7089 [online]. Available from URL: http://public.ukcrn.org.uk/search/Study Detail.aspx?StudyID=7089 [Accessed 2009 Jul 11]
33. Petry N. Contingency management treatments: a uniquely American approach, or perhaps even better suited for European drug abuse treatment? Br J Psychiatry 2006; 189: 97-98
34. LaGrow SJ, Repp AC. Stereotypic responding: a review of intervention research. Am J Mental Defic Res 1984; 88: 595-609
35. Scotti JR, Evans IM, Meyer LH, et al. A meta-analysis of intervention research with problem behaviour: treatment validity and standards of practice. Am J Ment Retard 1991; 93: 233-256
36. Peck Peterson SM, Caniglia C, Royster AJ, et al. Blending functional communication training and choice making to improve task engagement and decrease problem behaviour. Educ Psychol 2005; 25: 257-274
37. Shogren KA, Faggella-Luby M, Bae SJ, et al. The effect of choice-making as an intervention for problem behaviour: a meta-analysis. J Pos Behav Interventions 2004; 6: 228-237
38. Hassiotis A, Rowbotham D, Canagasaby A, et al. A randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities. Am J Psychiatry. In press
39. Haddock K, Jones RS. Practitioner consensus in the use of cognitive behaviour therapy for individuals with a learning disability. J Intellect Disabil 2006; 10: 221-230
40. Browder DM, Bambara LM, Belfiore PJ. Using a personcentred approach in community-based institutions for adults with developmental disabilities. J Behav Educ 1997; 7: 519-528
41. Hammel J. Technology and the environment: supportive resource or barrier for people with developmental disabilities? Nurs Clin North Am 2003; 38: 331-349
42. Tyrer P, Bajaj P. Nidotherapy: making the environment do the therapeutic work. Adv Psychiatric Treat 2005; 11: 232-238
43. Tyrer P, Kramo K. Nidotherapy in practice. J Ment Health 2007; 16: 117-131
44. Merrick J, Cahana C, Lotan M, et al. Snoezelen or controlled multisensory stimulation: treatment aspects from Israel. Scient World J 2004; 4: 307-314
45. Chung JC, Lai CK, Chung PM, et al. Snoezelen for dementia. Cochrane Database Syst Rev 2002; (4): CD003152
46. Savarithmu D, Bunnell T. The effects of music on clients with learning disabilities: a literature review. Complement Ther Nurs Midwifery 2002 Aug 8; 3: 160-165
47. Oliver PC, Piachaud J, Done J, et al. Difficulties in conducting a randomised controlled trial of health service interventions in intellectual disability: implications for evidence-based practice. J Intellect Disabil Res 2002; 46: 340-345
48. Willner P. The effectiveness of psychotherapeutic interventions for people with learning disabilities: a critical overview. J Intellect Disabil Res 2005; 49: 73-85
49. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side effects of antipsychotics in a randomized trial: findings from the CATIE Schizophrenia Trial. Br J Psychiatry 2008; 193: 279-288
50. Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials. J Intellect Disabil Res 1999; 43: 360-371 (Pubitemid 29495562)
51. La Malfa G, Lassi S, Bertelli M, et al. Reviewing the use of antipsychotic drugs in people with intellectual disability. Hum Psychopharmacol 2006; 21: 73-89
52. Ahmed Z, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 2000; 176: 42-46
53. Bekelman JE, Li Y, Gross PC. Scope and impact of financial conflict of interest in biomedical research: a systematic review. JAMA 2003; 289: 454-465
54. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 2007; 191: 82-83
55. Buitelaar JK, Van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62: 239-248
56. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89: 485-491
57. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-1346
58. McDougle CJ, Scahill L, Aman MG, etal. Risperidone for the core symptom domains of autism: results from the study by the autism network ofthe research units on pediatric psycho-pharmacology. Am J Psychiatry 2005; 162: 1142-1148
59. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioural problems. New Engl J Med 2002; 347: 314-320
60. McDougle CJ, Stigler KA, Erickson CA, et al. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008; 69 Suppl. 4: 15-20
61. Janowsky DS, Kraus JE, Barnhill LJ, et al. Effects of topiramate on aggressive, self-injurious, and disruptive/ destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 2003; 23: 500-504
62. Stolker JJ, Heerdink ER, Leufkens HG, et al. Determinants of multiple psychotropic use in patients with mild intellectual disabilities or borderline intellectual function and psychiatric or behavioural disorders. Gen Hosp Psychiatry 2001; 23: 345-349
63. Rangecroft MEH, Tyrer SP, Berney TP. The use of seclusion and emergency medication in a hospital for people with learning disability. Br J Psychiatry 1997; 170: 273-277
64. Fisher WW, Adelinis JD, Volkert VM, et al. Assessing preferences for positive and negative reinforcement during treatment of destructive behaviour with functional communication training. Res Development Disabil 2005; 26: 153-168
65. Tyrer P, Sensky T, Mitchard S. The principles of nidotherapy in the treatment of persistent mental and personality disorders. Psychother Psychosom 2003; 72: 350-356
66. Stirling C, McHugh A. Developing a non-aversive intervention strategy in the management of aggression and violence for people with learning disabilities using natural therapeutic holding. J Adv Nurs 1998; 27: 503-509
67. Hassiotis A, Hall I. Behavioural and cognitive-behavioural interventions for outwardly-directed aggressive behaviour in people with learning disabilities. Cochrane Database Syst Rev 2004 Oct 18; (4): CD003406
68. Hassiotis AA, Hall I. Behavioural and cognitive-behavioural interventions for outwardly-directed aggressive behaviour in people with learning disabilities. Cochrane Database Syst Rev 2008 Jul 16; (3): CD0034062008
69. Tyrer P, Oliver-Africano P, Romeo R, et al. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID trial). Health Technol Assess 2009; 13 (21): iii-iv, ix-xi, 1-54 70.
70. Morgan VA, Leonard H, Bourke J, et al. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. Br J Psychiatry 2008; 193: 364-372